Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

NCT05116475 is registered in ClinicalTrials.gov with Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie as lead sponsor.

NCT NCT05116475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Lead sponsor
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase
Phase 3
Overall status
Recruiting
Start date
August 30, 2022
Completion date
February 28, 2027
Enrollment
152 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer